Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 14/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6049755 | 1.00 | LTA4H (0.54) | LTA4HFFAR1L3MBTL1KDM4EMEN1 | |
| SCHEMBL6049744 | 0.96 | LTA4H (0.56) | LTA4HFFAR1L3MBTL1 | |
| SCHEMBL6049742 | 0.96 | LTA4H (0.56) | LTA4HFFAR1L3MBTL1 | |
| SCHEMBL6049748 | 0.93 | LTA4H (0.54) | LTA4HFFAR1L3MBTL1LMNAMAPK1 | |
| SCHEMBL6049751 | 0.93 | LTA4H (0.54) | LTA4HFFAR1L3MBTL1LMNAMAPK1 | |
| SCHEMBL6049799 | 0.88 | TDP1 (0.53) | LTA4HL3MBTL1ALDH1A1KMT2A | |
| Bromide SCHEMBL6049771 | 0.82 | LTA4H (0.56) | LTA4HL3MBTL1 | |
| Bromide SCHEMBL6049769 | 0.82 | LTA4H (0.56) | LTA4HL3MBTL1 | |
| SCHEMBL5681063 | 0.81 | LTA4H (0.57) | LTA4HL3MBTL1 | |
| Hydrochloric Acid SCHEMBL5679740 | 0.80 | LTA4H (0.55) | LTA4HL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878723-B1 | Carbocyclic and/or heterocyclic amino carboxylic acids, e.g., 2-aminomethyl-6-(p-benzylphenoxy)hexanoic acid; leukotriene A4 hydrolase; treating arthritis and psoriasis; hematoprotective and antimitotic agents | INSTITUT NATIONAL DE LA SANTE ET DE LA RESCHERCHE MEDICALE (INSERM) (FR) | 2005-04-12 | — | — | US | claimed |
| EP-1165491-B1 | LTA4 HYDROLASE INHIBITORS | INST NAT SANTE RECH MED (FR) | 2004-02-11 | — | — | EP | claimed |
| US-7094773-B2 | LTA4 hydrolase inhibitors | Institut National de la Santa et de la rescherche Medicale Bioprojet (FR) | 2006-08-22 | — | — | US | disclosed |
| US-6878723-B1 | Carbocyclic and/or heterocyclic amino carboxylic acids, e.g., 2-aminomethyl-6-(p-benzylphenoxy)hexanoic acid; leukotriene A4 hydrolase; treating arthritis and psoriasis; hematoprotective and antimitotic agents | INSTITUT NATIONAL DE LA SANTE ET DE LA RESCHERCHE MEDICALE (INSERM) (FR) | 2005-04-12 | — | — | US | disclosed |
| US-20050027013-A1 | LTA4 hydrolase inhibitors | DANVY DENIS (FR) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050027013-A1 | LTA4 hydrolase inhibitors | LTA4H, LTC4S, LTB4R | LTA4H 1/4885FFAR1 952/4885L3MBTL1 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.